NovaBridge Biosciences Depreciation & Amortization Growth & History (NBP)
NovaBridge Biosciences's depreciation and amortization was $68,000 for fiscal 2025.
View full NovaBridge Biosciences company overviewNovaBridge Biosciences annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $68,000 | −$232,000 | −77.33% |
| 2024 | 2024-12-31 | $300,000 | −$200,000 | −40.00% |
| 2023 | 2023-12-31 | $500,000 | $300,000 | +150.00% |
| 2022 | 2022-12-31 | $200,000 | −$2.1M | −91.24% |
| 2021 | 2021-12-31 | $2.3M | $93,000 | +4.24% |
| 2020 | 2020-12-31 | $2.2M | $779,000 | +55.17% |
| 2019 | 2019-12-31 | $1.4M | — | — |
NovaBridge Biosciences quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $216,000 | $3,000 | +1.41% |
| Q3 2025 | 2025-09-30 | $17,000 | −$3,000 | −15.00% |
| Q4 2024 | 2024-12-31 | $213,000 | — | — |
| Q3 2024 | 2024-09-30 | $20,000 | — | — |
NovaBridge Biosciences depreciation and amortization trends
Over the last five fiscal years, NovaBridge Biosciences's depreciation and amortization decreased from $2.2M to $68,000, a change of −$2.1M. The latest reported quarter, Q4 2025, shows $216,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovaBridge Biosciences source filings ↗